263 related articles for article (PubMed ID: 19593441)
1. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
2. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
[TBL] [Abstract][Full Text] [Related]
3. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
[No Abstract] [Full Text] [Related]
4. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.
Gu L; Lau SK; Loera S; Somlo G; Kane SE
Clin Cancer Res; 2009 Dec; 15(23):7196-206. PubMed ID: 19920112
[TBL] [Abstract][Full Text] [Related]
5. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
Belkhiri A; Dar AA; Peng DF; Razvi MH; Rinehart C; Arteaga CL; El-Rifai W
Clin Cancer Res; 2008 Jul; 14(14):4564-71. PubMed ID: 18579663
[TBL] [Abstract][Full Text] [Related]
6. t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit.
Theile D; Geng S; Denny EC; Momand J; Kane SE
Cell Signal; 2017 Dec; 40():53-61. PubMed ID: 28867659
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
8. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Christenson JL; Denny EC; Kane SE
Oncotarget; 2015 Oct; 6(32):33134-45. PubMed ID: 26430732
[TBL] [Abstract][Full Text] [Related]
9. t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.
Denny EC; Kane SE
PLoS One; 2015; 10(6):e0132267. PubMed ID: 26121470
[TBL] [Abstract][Full Text] [Related]
10. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
[TBL] [Abstract][Full Text] [Related]
11. t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism.
Belkhiri A; Dar AA; Zaika A; Kelley M; El-Rifai W
Cancer Res; 2008 Jan; 68(2):395-403. PubMed ID: 18199533
[TBL] [Abstract][Full Text] [Related]
12. Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
Chen B; Wang Y; Kane SE; Chen S
J Mol Endocrinol; 2008 Nov; 41(5):367-77. PubMed ID: 18768663
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
14. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
[TBL] [Abstract][Full Text] [Related]
15. Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.
Avanes A; Lenz G; Momand J
Biochem Pharmacol; 2019 Feb; 160():71-79. PubMed ID: 30552871
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
18. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
19. Development of Herceptin resistance in breast cancer cells.
Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
[TBL] [Abstract][Full Text] [Related]
20. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
